A Suspected Case of Alveolar Hemorrhage Caused by Osimertinib

Komori, Mai; Morimoto, Kenji; Date, Koji; Kawano, Hidehiko; Iwasaki, Yasushi

doi:10.2482/haigan.59.366

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Reviewing previous studies we found a total of three articles reporting, in 2019–2021, cases of diffuse alveolar hemorrhage induced by Osimertinib. 10,11,15 Despite the failure to explain the mechanism of Osimertinib-induced DAH, Komori et al scientists suggest that the direct toxicity of cytotoxic drugs on type II lung cells, tracheal epithelial cells and vascular endothelial cells, as well as the activation of immune system cells may play a key role. In 2018 Kazuki Hayasaka, a scientist from Japan, reported 1 case of papilla of Vater bleeding after Osimertinib treatment for pancreatic metastases from lung adenocarcinoma, but there was no further analysis of the possible causes.…”

Section: Discussionmentioning

confidence: 99%

Colonic mucosal diffuse congestion associated with Osimertinib

Ren

Lei

Cheng

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Non-small cell lung cancer (NSCLC) is the most common histological subtype of lung cancer. Osimertinib has been recommended as first-line treatment of advanced NSCLC with EGFR mutations. Previous studies have only reported cases of gastrointestinal bleeding due to Erlotinib and gefitinib, but to date, always no cases of gastrointestinal bleeding due to Osimertinib have been reported. Case Report We report a case of a female patient with NSCLC with EFGR mutation. After 1.5 years of treatment with Osimertinib, a colonoscopy showed diffuse congestion of the colonic mucosa. Management and Outcome The patient’s symptoms of blood in the stool disappeared, after stopping Osimertinib and giving mucosal protection treatment for 1 week. Discussion Osimertinib may have contributed to gastrointestinal bleeding because no recurrent bleeding was observed after discontinuation of treatment. Physicians and patients should be aware that osimertinib may increase the risk of gastrointestinal bleeding.

show abstract